• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Saad Kareem converted options into 273 shares, increasing direct ownership by 1% to 24,219 units (SEC Form 4)

    1/3/24 4:25:40 PM ET
    $SMFR
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $SMFR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Saad Kareem

    (Last) (First) (Middle)
    C/O GENEDX HOLDINGS CORP.
    333 LUDLOW ST, NORTH TOWER

    (Street)
    STAMFORD CT 06902

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    GeneDx Holdings Corp. [ WGS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Transformation Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    01/01/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 01/01/2024 M 273 A $0.00(1) 24,219 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) 01/01/2024 M 273 (2) (2) Class A Common Stock 273 $0.00 2,455 D
    Explanation of Responses:
    1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
    2. 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date
    Remarks:
    /s/ Devin Schaffer, Attorney-in-Fact 01/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SMFR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMFR

    DatePrice TargetRatingAnalyst
    12/7/2022$3.00 → $1.00Buy → Neutral
    Goldman
    8/16/2022$4.00 → $2.00Buy → Hold
    Jefferies
    6/2/2022$3.50Buy
    Goldman
    11/19/2021$12.00Buy
    Goldman Sachs
    10/8/2021$12.00Buy
    BTIG Research
    9/30/2021$13.00Outperform
    Cowen & Co.
    9/24/2021$13.00Buy
    Jefferies
    More analyst ratings

    $SMFR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Saad Kareem sold $625 worth of shares (193 units at $3.24) and converted options into 546 shares, increasing direct ownership by 1% to 24,467 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/23/24 4:10:20 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Ryan Jason gifted 73,614 shares, closing all direct ownership in the company (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/12/24 4:31:01 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Saad Kareem sold $271 worth of shares (105 units at $2.58), decreasing direct ownership by 0.43% to 24,114 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      1/4/24 5:03:07 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ryan Jason bought $161,368 worth of shares (114,742 units at $1.41) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      11/20/23 4:32:17 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Pfenniger Richard C Jr bought $14,889 worth of shares (10,000 units at $1.49), increasing direct ownership by 92% to 20,918 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      11/8/23 7:19:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Leadership Updates

    Live Leadership Updates

    See more
    • Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

      STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position. Mr. Feeley, who has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022, will also continue to lead all key operational aspects of the Company. "As we shared during our recent earnings call, our new management team is committed to profitable growth, efficiency, and scale. Kevin's broad industry experience and successful financial leadership of GeneDx during an accelerated phase of commercial

      8/26/22 8:00:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Announces Chief Financial Officer Transition Plan

      Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4's Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. "We are extremely thankful fo

      6/14/22 4:30:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Sema4 Holdings Corp.

      SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)

      2/9/24 7:10:06 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/17/23 4:15:23 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form SC 13G/A filed by Sema4 Holdings Corp. (Amendment)

      SC 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)

      6/9/23 4:15:22 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

      Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

      1/9/23 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

      STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming

      12/30/22 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

      STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai

      12/5/22 8:00:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Financials

    Live finance-specific insights

    See more
    • Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

      Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and

      1/9/23 8:30:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

      Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity

      11/14/22 8:02:00 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

      STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast

      11/4/22 4:05:00 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    SEC Filings

    See more
    • Sema4 Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GeneDx Holdings Corp. (0001818331) (Filer)

      1/8/24 8:58:39 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by Sema4 Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      11/15/23 5:17:42 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 10-Q filed by Sema4 Holdings Corp.

      10-Q - GeneDx Holdings Corp. (0001818331) (Filer)

      11/3/23 4:06:35 PM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology

    $SMFR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sema4 Holdings Corp downgraded by Goldman with a new price target

      Goldman downgraded Sema4 Holdings Corp from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      12/7/22 8:08:36 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Sema4 Holdings Corp downgraded by Jefferies with a new price target

      Jefferies downgraded Sema4 Holdings Corp from Buy to Hold and set a new price target of $2.00 from $4.00 previously

      8/16/22 7:58:53 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Goldman resumed coverage on Sema4 Holdings Corp with a new price target

      Goldman resumed coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $3.50

      6/2/22 7:21:25 AM ET
      $SMFR
      Retail: Computer Software & Peripheral Equipment
      Technology